Diadema Partners’s Aprea Therapeutics APRE Stock Holding History
Bought
Maintained
Sold
Other funds holding APRE
ACM
Diadema Partners's APRE Position: Q3 2026 in Review
Diadema Partners reduced its Aprea Therapeutics (APRE) stake by 36% in Q3 2026, selling an estimated $11.6K and leaving 28,872 shares worth $21.7K. The position accounts for ﹤0.01% of the portfolio, ranked #138.
Diadema Partners first reported a position in APRE in Q2 2026 and has held it in 2 quarters since. The position peaked at $36K in Q2 2026. 28 funds tracked by Wall St. Rank hold APRE as of Q3 2026.
- Diadema Partners held 28,872 shares of Aprea Therapeutics worth $21.7K as of Q3 2026.
- Diadema Partners sold 16,035 Aprea Therapeutics shares in Q3 2026, an estimated $11.6K.
- Aprea Therapeutics made up ﹤0.01% of Diadema Partners's portfolio in Q3 2026, its #138 holding.
- Diadema Partners first reported a position in Aprea Therapeutics in Q2 2026 and has held it in 2 quarters since.
- Diadema Partners's Aprea Therapeutics position peaked at $36K in Q2 2026.
- 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2026.
Based on Diadema Partners's 13F filing for Q3 2026, filed 16 Nov 2026.